CoChat

Microhaplotype deep sequencing assays to capture Plasmodium vivax infection lineages

Kleinecke, Mariana, Sutanto, Edwin, Rumaseb, Angela, Hoon, Kian Soon, Trimarsanto, Hidayat, Osborne, Ashley, Manrique, Paulo, Peters, Trent, Hawkes, David, Benavente, Ernest Diez, Whitton, Georgia, Siegel, Sasha V., Pearson, Richard D., Amato, Roberto, Rai, Anjana, Nhien, Nguyen Thanh Thuy, Nguyen, Hoang Chau, Assefa, Ashenafi, Degaga, Tamiru S., Abate, Dagimawie Tadesse, Rahim, Awab Ghulam, Pasaribu, Ayodhia Pitaloka, Sutanto, Inge, Alam, Mohammad Shafiul, Pava, Zuleima, Lopera-Mesa, Tatiana, Echeverry, Diego, William, Tim, Anstey, Nicholas M., Grigg, Matthew J., Day, Nicholas P., White, Nicholas J., Kwiatkowski, Dominic P., Taylor, Aimee R., Noviyanti, Rintis, Neafsey, Daniel, Price, Ric N., Auburn, Sarah · 2025 · Nature Communications

Published version of a preprint

Cited by 19

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Plasmodium vivax elimination is challenged by dormant liver stages (hypnozoites) that can reactivate months after initial infection resulting in relapses. Relapsing infections confound antimalarial clinical efficacy trials due to the inability to distinguish between recurrences arising from blood-stage treatment failure (recrudescence), reinfection or relapse. Genetic relatedness of paired parasite isolates, measured by identity-by-descent (IBD), can provide important information on whether individuals have had single or multiple mosquito inoculations, thus informing on recurrence origin. We developed a high-throughput amplicon sequencing assay comprising 93 multi-SNP (microhaplotype) markers to determine IBD between P. vivax clinical isolates. The assay was evaluated in 745 global infections, including 128 infection pairs from a randomized controlled trial (RCT) (ClinicalTrials.gov NCT01680406). Simulations demonstrate low error in pairwise IBD estimation at the panel (RMSE < 0.12) and IBD-based networks illustrate strong clustering by geography. IBD analysis in the RCT demonstrates a lower frequency of suspected relapses or recrudescence in patients treated with primaquine compared to those without primaquine; the impact is greater when paired with chloroquine than with artemether-lumefantrine. Our results demonstrate the potential to derive new information on P. vivax treatment and transmission using IBD generated by amplicon sequencing data that can be further improved with time-to-event models.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-025-62357-x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 63

  1. Auburn, S., Cheng, Q., Marfurt, J. & Price, R. N. The changing epidemiology of Plasmodium vivax: Insights from conventional and novel surveillance tools. PLoS Med. 18, e1003560 (2021). · DOI · Paper page
  2. Douglas, N. M. et al. Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia. BMC Med. 12, 217 (2014). · DOI
  3. Commons, R. J. et al. Primaquine for uncomplicated Plasmodium vivax malaria in children younger than 15 years: a systematic review and individual patient data meta-analysis. Lancet Child Adolesc. Health 8, 798–808 (2024). · doi:10.1016/s2352-4642(24)00210-4
  4. Verma, R. et al. Safety and efficacy of primaquine in patients with Plasmodium vivax malaria from South Asia: a systematic review and individual patient data meta-analysis. BMJ Glob. Health 8, https://doi.org/10.1136/bmjgh-2023-012675 (2023). · DOI
  5. Mehdipour, P. et al. Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. Malar. J. 22, 306 (2023). · DOI
  6. Rajasekhar, M. et al. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis. Lancet Infect. Dis. 24, 184–195 (2024). · DOI · Paper page
  7. Commons, R. J. et al. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis. Lancet Infect. Dis. 24, 172–183 (2024). · DOI · Paper page
  8. White, N. J. & Imwong, M. Relapse. Adv. Parasitol. 80, 113–150 (2012). · DOI · Paper page
  9. Snounou, G. & Beck, H. P. The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol. Today 14, 462–467 (1998). · DOI · Paper page
  10. Imwong, M. et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J. Infect. Dis. 195, 927–933 (2007). · DOI · Paper page
  11. Chen, N., Auliff, A., Rieckmann, K., Gatton, M. & Cheng, Q. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J. Infect. Dis. 195, 934–941 (2007). · DOI · Paper page
  12. Abdullah, N. R. et al. Plasmodium vivax population structure and transmission dynamics in Sabah Malaysia. PloS one 8, e82553 (2013). · DOI
  13. Bright, A. T. et al. A high resolution case study of a patient with recurrent Plasmodium vivax infections shows that relapses were caused by meiotic siblings. PLoS Neglect. Tropic. Dis. 8, e2882 (2014). · DOI · Paper page
  14. Popovici, J. et al. Genomic Analyses Reveal the Common Occurrence and Complexity of Plasmodium vivax Relapses in Cambodia. mBio 9, https://doi.org/10.1128/mBio.01888-17 (2018). · DOI
  15. Ruybal-Pesantez, S. et al. Molecular markers for malaria genetic epidemiology: progress and pitfalls. Trends Parasitol. 40, 147–163 (2024). · DOI · Paper page
  16. Abreha, T. et al. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial. PLoS Med. 14, e1002299 (2017). · DOI · Paper page
  17. Battle, K. E. et al. Geographical variation in Plasmodium vivax relapse. Malar. J. 13, 144 (2014). · DOI · Paper page
  18. Jacob, C. G. et al. Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination. eLife 10, https://doi.org/10.7554/eLife.62997 (2021). · DOI · Paper page
  19. Price, R. N., Auburn, S., Marfurt, J. & Cheng, Q. Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax. Trends Parasitol. 28, 522–529 (2012). · DOI
  20. Suwanarusk, R. et al. Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PloS one 2, e1089 (2007). · DOI · Paper page
  21. Groves, E. S. et al. Parasitaemia and fever in uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis. PLoS Neglect. Tropic. Dis. 19, e0012951 (2025). · DOI
  22. Cowell, A. N. et al. Selective whole-genome amplification is a robust method that enables scalable whole-genome sequencing of Plasmodium vivax from unprocessed clinical samples. mBio 8, https://doi.org/10.1128/mBio.02257-16 (2017). · DOI
  23. Arneson, N., Hughes, S., Houlston, R. & Done, S. Whole-genome amplification by improved primer extension preamplification PCR (I-PEP-PCR). CSH Protoc. 2008, pdb prot4921 (2008).
  24. Baniecki, M. L. et al. Development of a single nucleotide polymorphism barcode to genotype Plasmodium vivax infections. PLoS Neglect. Tropic. Dis. 9, e0003539 (2015). · DOI · Paper page
  25. Taylor, A. R., Jacob, P. E., Neafsey, D. E. & Buckee, C. O. Estimating relatedness between malaria parasites. Genetics 212, 1337–1351 (2019). · DOI · Paper page
  26. Taylor, A. R. et al. Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. Nat. Commun. 10, 5595 (2019). · DOI · Paper page
  27. Karunajeewa, H. A. et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N. Engl. J. Med. 359, 2545–2557 (2008). · DOI · Paper page
  28. Baird, J. K. 8-aminoquinoline therapy for latent malaria. Clin. Microbiol. Rev. 32, https://doi.org/10.1128/CMR.00011-19 (2019). · DOI · Paper page
  29. Anstey, N. M. et al. The biology and pathogenesis of vivax malaria. Trends Parasitol. 40, 573–590 (2024). · DOI
  30. Trimarsanto, H. et al. A molecular barcode and web-based data analysis tool to identify imported Plasmodium vivax malaria. Commun. Biol. 5, 1411 (2022). · DOI · Paper page
  31. Buyon, L. E., Elsworth, B. & Duraisingh, M. T. The molecular basis of antimalarial drug resistance in Plasmodium vivax. Int. J. Parasitol. Drugs Drug Resist. 16, 23–37 (2021). · DOI
  32. Ratcliff, A. et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans. R. Soc. Tropic. Med. Hyg. 101, 351–359 (2007). · DOI · Paper page
  33. Pearson, R. D. et al. Genomic analysis of local variation and recent evolution in Plasmodium vivax. Nat. Genet. 48, 959–964 (2016). · DOI · Paper page
  34. Assefa, M., Eshetu, T. & Biruksew, A. Therapeutic efficacy of chloroquine for the treatment of Plasmodium vivax malaria among outpatients at Hossana Health Care Centre, southern Ethiopia. Malar. J. 14, 458 (2015). · DOI · Paper page
  35. Getachew, S. et al. Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia. Malar. J. 14, 525 (2015). · DOI · Paper page
  36. Thuan, P. D. et al. A randomized comparison of chloroquine versus dihydroartemisinin-piperaquine for the treatment of Plasmodium vivax infection in Vietnam. Am. J. Tropic. Med. Hyg. 94, 879–885 (2016). · doi:10.4269/ajtmh.15-0740
  37. Phong, N. C. et al. Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam. Malar. J. 18, 10 (2019). · DOI
  38. Kolaczinski, K., Durrani, N., Rahim, S. & Rowland, M. Sulfadoxine-pyrimethamine plus artesunate compared with chloroquine for the treatment of vivax malaria in areas co-endemic for Plasmodium falciparum and P. vivax: a randomised non-inferiority trial in eastern Afghanistan. Trans. R. Soc. Tropic. Med. Hyg. 101, 1081–1087 (2007). · DOI
  39. Leslie, T. et al. Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial. JAMA 297, 2201–2209 (2007). · doi:10.1001/jama.297.20.2201
  40. Awab, G. R. et al. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Malar. J. 9, 105 (2010). · DOI
  41. Sutanto, I. et al. Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia. Malar. J. 9, 52 (2010). · DOI
  42. Fryauff, D. J. et al. The drug sensitivity and transmission dynamics of human malaria on Nias Island, North Sumatra, Indonesia. Ann. Trop. Med Parasitol. 96, 447–462 (2002). · DOI
  43. Ley, B. et al. G6PD deficiency and antimalarial efficacy for uncomplicated Malaria in Bangladesh: A Prospective Observational Study. PloS one 11, e0154015 (2016). · DOI
  44. Castillo, C. M., Osorio, L. E. & Palma, G. I. Assessment of therapeutic response of Plasmodium vivax and Plasmodium falciparum to chloroquine in a Malaria transmission free area in Colombia. Mem. do Inst. Oswaldo Cruz 97, 559–562 (2002). · DOI
  45. Mesa-Echeverry, E., Niebles-Bolivar, M. & Tobon-Castano, A. Chloroquine-primaquine therapeutic efficacy, safety, and plasma levels in patients with uncomplicated Plasmodium vivax Malaria in a Colombian Pacific Region. Am. J. Tropic. Med. Hyg. 100, 72–77 (2019). · DOI · Paper page
  46. Perez, M. A. et al. Efficacy of the amodiaquine+sulfadoxine-pyrimethamine combination and of chloroquine for the treatment of malaria in Cordoba, Colombia, 2006]. Biomedica 28, 148–159 (2008). · DOI
  47. Alvarez, G. et al. Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia. Am. J. Tropic. Med. Hyg. 75, 605–609 (2006). · DOI
  48. Higgins, M. et al. New reference genomes to distinguish the sympatric malaria parasites, Plasmodium ovale curtisi and Plasmodium ovale wallikeri. Sci. Rep. 14, 3843 (2024). · DOI
  49. Popkin-Hall, Z. R. et al. High-throughput genotyping of Plasmodium vivax in the Peruvian Amazon via molecular inversion probes. Nat. Commun. 15, 10219 (2024). · DOI · Paper page
  50. Fola, A. A. et al. SNP barcodes provide higher resolution than microsatellite markers to measure Plasmodium vivax population genetics. Malar. J. 19, 375 (2020). · DOI
  51. Kattenberg, J. H. et al. Novel highly-multiplexed AmpliSeq targeted assay for Plasmodium vivax genetic surveillance use cases at multiple geographical scales. Front. Cell. Infect. Microbiol. 11, https://doi.org/10.3389/fcimb.2022.953187 (2022). · DOI
  52. MalariaGen et al. An open dataset of Plasmodium vivax genome variation in 1,895 worldwide samples. Wellcome Open Res. 7, 136 (2022). · DOI · Paper page
  53. Taylor, W. R. J. et al. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet 394, 929–938 (2019). · DOI · Paper page
  54. Grigg, M. J. et al. Artesunate-mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial. Lancet Infect. Dis. 16, 180–188 (2016). · DOI
  55. Gruenberg, M. et al. Plasmodium vivax molecular diagnostics in community surveys: pitfalls and solutions. Malar. J. 17, 55 (2018). · DOI
  56. Auburn, S. et al. A new Plasmodium vivax reference sequence with improved assembly of the subtelomeres reveals an abundance of pir genes. Wellcome Open Res. 1, 4 (2016). · DOI
  57. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009). · DOI · Paper page
  58. LaVerriere, E. et al. Design and implementation of multiplexed amplicon sequencing panels to serve genomic epidemiology of infectious disease: a malaria case study. Mol. Ecol. Resour. 22, 2285–2303 (2022). · DOI
  59. Murphy, M. & Greenhouse, B. MOIRE: A software package for the estimation of allele frequencies and effective multiplicity of infection from polyallelic data. Bioinformatics, 40, btae619 (2024). · DOI
  60. Auburn, S. et al. Characterization of within-host Plasmodium falciparum diversity using next-generation sequence data. PloS one 7, e32891 (2012). · DOI · Paper page
  61. Gerlovina, I., Gerlovin, B., Rodriguez-Barraquer, I. & Greenhouse, B. Dcifer: an IBD-based method to calculate genetic distance between polyclonal infections. Genetics 222, https://doi.org/10.1093/genetics/iyac126 (2022). · DOI · Paper page
  62. Paradis, E., Claude, J. & Strimmer, K. APE: analyses of phylogenetics and evolution in R language. Bioinformatics 20, 289–290 (2004). · DOI · Paper page
  63. Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32, 1792–1797 (2004). · DOI · Paper page

Cited by

See all 19

Metadata

Authors
Kleinecke, M., Sutanto, E., Rumaseb, A., Hoon, K. S., Trimarsanto, H., Osborne, A., Manrique, P., Peters, T., Hawkes, D., Benavente, E. D., Whitton, G., Siegel, S. V., Pearson, R. D., Amato, R., Rai, A., Nhien, N. T. T., Nguyen, H. C., Assefa, A., Degaga, T. S., Abate, D. T., Rahim, A. G., Pasaribu, A. P., Sutanto, I., Alam, M. S., Pava, Z., Lopera-Mesa, T., Echeverry, D., William, T., Anstey, N. M., Grigg, M. J., Day, N. P., White, N. J., Kwiatkowski, D. P., Taylor, A. R., Noviyanti, R., Neafsey, D., Price, R. N., & Auburn, S.
Venue
Nature Communications
Published
2025-08-05
Volume
16
Issue
1
ISSN
2041-1723
Cited by
19
References
3
Language
en
Licence
Funders
  • Bill and Melinda Gates Foundation (INV-043618)
  • Department of Health | National Health and Medical Research Council (APP2001083)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Microhaplotype deep sequencing assays to capture Plasmodium vivax infection lineages. https://app.cochat.ai/papers/10.1038/s41467-025-62357-x
The paper
Kleinecke, M., Sutanto, E., Rumaseb, A., Hoon, K. S., Trimarsanto, H., Osborne, A., Manrique, P., Peters, T., Hawkes, D., Benavente, E. D., Whitton, G., Siegel, S. V., Pearson, R. D., Amato, R., Rai, A., Nhien, N. T. T., Nguyen, H. C., Assefa, A., Degaga, T. S., . . . Auburn, S. (2025). Microhaplotype deep sequencing assays to capture Plasmodium vivax infection lineages. Nature Communications. https://doi.org/10.1038/s41467-025-62357-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.